Previous close | 1.0000 |
Open | N/A |
Bid | 0.0000 |
Ask | 4.0000 |
Strike | 42.50 |
Expiry date | 2025-01-17 |
Day's range | 1.0000 - 1.0000 |
Contract range | N/A |
Volume | |
Open interest | 5 |
The FDA grants priority review to Ionis' (IONS) filing seeking approval for olezarsen to treat adults with familial chylomicronemia syndrome. A final decision is expected in December 2024.
A Relative Strength Rating upgrade for Novartis ADR shows improving technical performance. Will it continue?
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.